The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
British Journal of Pharmacology · 2026-03 · 183 (6) · 1250-1270
DOI: 10.1111/bph.16313 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 07.02.2024. Verfasst von Mikhaël Attias und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Tumor Microenvironment, T-Lymphocytes, Regulatory, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events. The consequences of checkpoint inhibition on Foxp3 + regulatory T (T reg ) cells remain unclear but could provide key insights into these variable outcomes. In this review, we first cover the mechanisms that underlie the development of hot and cold tumour microenvironments, which determine the efficacy of immunotherapy. We then outline how differences in tumour‐intrinsic immunogenicity, T‐cell trafficking, local metabolic environments and inhibitory checkpoint signalling differentially impair CD8 + T‐cell function in tumour microenvironments, all the while promoting T reg ‐cell suppressive activity. Finally, we focus on the mechanisms that enable the induction of polyfunctional CD8 + T‐cells upon checkpoint blockade and discuss the role of ICI‐induced T reg ‐cell reactivation in acquired resistance to treatment. LINKED ARTICLES This article is part of a themed issue Immunotherapy in Cancer. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.6/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
- Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, Québec, Canada.
- Centre of Excellence in Translational Immunology (CETI), The Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, Québec, Canada.
ORCID-Profile: Mikhaël Attias, Ciriaco A Piccirillo
Zitieren
APA
Attias, M., & Piccirillo, C. A. (2026). The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors. British Journal of Pharmacology, 183(6), 1250-1270. https://doi.org/10.1111/bph.16313
Vancouver
Attias M, Piccirillo CA. The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors. British Journal of Pharmacology. 2026;183(6):1250-1270. doi:10.1111/bph.16313
BibTeX
@article{Attias2026,
author = {Attias, Mikhaël and Piccirillo, Ciriaco A},
title = {The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {6},
pages = {1250--1270},
doi = {10.1111/bph.16313}
}
EUVIMED